AAM All Access Podcast - Dan Leonard speaks to David Gaugh (AAM), Jessica Daley (Premier Inc) and Steven Schondelmeyer (University of Minnesota).

AAM Calls on FTC to Investigate PBM Business Practices

“A distinct set of PBM business practices have resulted in higher prices and delayed access to generics and biosimilars for patients,” said AAM CEO Dan Leonard.

Read Press Release
Featured AAM All Access Podcast: Managing Drug Shortages

What’s a drug shortage? AAM CEO Dan Leonard speaks to 3 eminent pharmacists, each with different insights into management and mitigation of drug shortages: David Gaugh (AAM), Jessica Daley (Premier Inc.) and Steven Schondelmeyer (University of Minnesota).

Listen to Podcast
VETO Illinois HB 1780 Which Puts Patient Access to Generics at Risk!

Generics drive patient savings, yet HB 1780 imposes new costs on patients who rely on generics access to life-saving treatments.

Learn More
Who’s Profiting from Your Prescription?

Unlike brand drugs where the manufacturer stands to profit the most, generic medicines are often exploited by middlemen that seize significant profits at the expense of patients and the companies that make the medicines.

Learn More
GRx+Biosims 2022 Early Bird Special

Registration is open! Sign up now for the early bird discount and $500 off a GRx+Biosims conference full-pass registration! November 7-9, 2022 in North Bethesda, Maryland.

Register Now
Generic Medicines Are Saving Your State Billions

In 2020, generic and biosimilar medicines saved America's patients $338 billion. Find out how much your state saved with our interactive savings map.

View Interactive Map
AAM Voices of Access

Physicians, pharmacists, patients and caregivers across the country trust generics and biosimilars. Here are their stories, in their own words—along with perspectives from health care professionals and the AAM team.

View Report
Prescription for State Savings

State lawmakers can take meaningful action to lower brand prescription drug costs with the Prescription for State Savings. AAM outlines several solutions states could pursue.

Learn More
AAM Encourages Congress to Protect Patient Savings

Competition from lower-cost generics and biosimilars has successfully led to decades of savings for patients. AAM strongly opposes negotiations in Medicare that would jeopardize these savings.

Learn More

Working to leave a positive impact on...

Industry

We promote competition in the pharmaceutical industry by lowering barriers to entry for manufacturers of generic and biosimilar medicines and combatting anti-competitive abuses by some brand drug companies who put profits before patients. Learn More

People

We measure our success as an industry by the lives we impact. We work to protect the low cost of generic and biosimilar medicines and to drive down the cost of developing new ones, expanding access to as many people as possible. Learn More

Policy

We are a trusted partner and established authority within the pharmaceutical field. We provide accurate, timely data to educate policymakers and promote general public knowledge regarding the positive impact of affordable generic and biosimilar medicines. Learn More

About Us

The Association for Accessible Medicines improves access to safe, quality, effective medicine. Better access to medicine is relevant to everybody because, after all, we’re all patients at some point.

Health is the foundation for everything in life. Healthy people are better able to reach their full potential. Generics and biosimilars help more people in more places live healthier and longer.

Recent Updates

Video

May 24, 2022 | Erica Klinger

Sandoz US Leadership on the Value and Promise of #RemarkablyGeneric

Ariel with Medicines

May 23, 2022 | Monét Stanford

AAM Calls for Federal Trade Commission to Investigate PBM Business Practices

Ariel with Medicines

May 23, 2022 | Allen Goldberg

AAM Statement in Response to Federal Trade Commission Request for Information on PBM Business Practices

May 16, 2022 | Allen Goldberg

Association for Accessible Medicines Names Craig Burton as Senior Vice President, Policy & Strategic Alliances, and Executive Director of the Biosimilars Council

Headquarter of the U.S. Food and Drug Administration (FDA)

May 11, 2022 | Allen Goldberg

AAM Statement on House Energy and Commerce Health Subcommittee Markup of H.R. 7667 Reauthorizing Generic Drug and Biosimilar User Fee Amendments

IQVIA The Use of Medicines in the U.S. 2022 Report

May 2, 2022 | Monét Stanford

Generics Drive Savings Yet Patients Continue to Pay More